(Q34240764)

31 July 2017

1 reference

title

Current treatment for ovarian cancer (English)

1 reference

31 July 2017

1 reference

Eltabbakh GH

1

1 reference

31 July 2017

Awtrey CS

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 January 2001

1 reference

Expert Opinion on Pharmacotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

2

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

109-124

1 reference

31 July 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.109

Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.109

Controversial issues in the management of early epithelial ovarian cancer: conservative surgery and role of adjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.109

A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.109

High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.109

Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.109

A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.109

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.109

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.109

Sequences of taxol and cisplatin: a phase I and pharmacologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.109

Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.109

Topotecan in platinum- and paclitaxel-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.109

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.109

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.1.109

21 January 2018

Identifiers

DOI

10.1517/14656566.2.1.109

1 reference

31 July 2017

1 reference